About Us

MyUvealMelanoma.com was created for people who have just been diagnosed with this rare cancer. We provide a lot of information about the disease and its treatment, as well as great resources. But our main goal is to make patients aware of a genomic test that can help determine whether the tumor will metastasize, or spread to other parts of the body.

castle_logoUp to half of uveal melanoma patients will ultimately develop fatal metastases, so monitoring and follow-up after eye surgery are critical. The prognostic test, DecisionDx-UM, is a highly accurate predictor of metastatic risk. It is being used by the majority of ocular oncologists to individualize their patients’ care plans after surgery with the hopes of earlier detection and intervention.

Our company, Castle Biosciences, works with leading cancer treatment centers to develop molecular tests like DecisionDx-UM to help patients and physicians achieve better outcomes in rare cancers. We strongly believe that it is up to each patient, in discussion with their doctor, to determine whether they want to know their metastatic risk. So we’ve dedicated this site to providing a comprehensive and factual basis for making that decision.


Know your TYPE, Know your RISK
You’ve just been diagnosed with uveal melanoma, and it’s important to know that there is a test that can identify your tumor type—and the risk of your cancer spreading.

GETTING TESTED       Timing is Critical
To know your tumor type and risk, a biopsy must be taken BEFORE radiation treatment.

Talk to                 Your Doctor
Use this discussion guide to talk to your doctor about the genomic test to learn your tumor type, or CLASS.


Sign Up For Updates

Please leave this field empty.

Share on Facebook+1Share on Twitter

Share Your Stories

There's comfort in knowing you are not alone. If you or a loved one have experienced uveal melanoma and would like to help encourage others whose lives have been touched by this disease, please share your story with us.
Start Sharing